Naloxona B. Braun (Naloxone Hydrochloride)

Naloxone is used in the management of opioid‑related emergencies, acting to reverse the pharmacologic effects of opioid agonists.

• Opioid overdose: immediate reversal of life‑threatening respiratory depression and sedation.
• Opioid‑induced respiratory depression: restores normal breathing in acute settings.
• Opioid toxicity in emergency care: enables rapid recovery of consciousness and cardiovascular stability.
• Opioid‑induced hypotension: helps normalize blood pressure in acute overdose.

• Naloxone acts as a competitive antagonist at μ‑opioid receptors and, to a lesser extent, at κ‑ and δ‑opioid receptors. By binding without activating the receptor, it displaces opioid agonists such as morphine, fentanyl or heroin, thereby terminating their analgesic and respiratory‑depressant effects. The rapid receptor blockade restores neuronal activity in the brainstem respiratory centers, leading to prompt improvement in ventilation and consciousness.

Naloxone may be associated with a range of adverse reactions, most of which are transient and related to abrupt opioid withdrawal.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Vomiting: occasional emesis following administration.
• Sweating: increased perspiration.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Severe hypertension: sudden rise in blood pressure.
• Cardiac arrhythmia: irregular heart rhythm.
• Pulmonary edema: fluid accumulation in lungs.
• Anaphylaxis: severe allergic reaction requiring immediate treatment.

When using Naloxona B. Braun, clinicians should observe specific safety measures to minimize risks and ensure effective reversal of opioid toxicity.

• Assess airway and breathing before administration: confirm respiratory compromise and need for opioid antagonist.
• Use only when opioid overdose is suspected: verify clinical signs such as pinpoint pupils, unconsciousness, or respiratory depression.
• Prefer intramuscular route unless intravenous access is established: reduces risk of intravascular injection complications.
• Monitor cardiovascular status after dosing: watch for hypertension, tachycardia, or arrhythmias.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxona B. Braun can interact with other medicines, influencing its safety or the response to concomitant drugs.

Major Interactions (Avoid)

• Concurrent use of potent sympathomimetics: may exacerbate hypertension after naloxone administration.
• Combination with other opioid antagonists: can increase the intensity of withdrawal symptoms.

Moderate Interactions (Monitor Closely)

• Ongoing opioid therapy: naloxone may precipitate withdrawal; adjust opioid dosing as needed.
• Beta‑blockers: may mask tachycardia that signals adverse cardiovascular response.
• Antihypertensive agents: blood pressure should be monitored because naloxone can cause transient hypertension.